Search

Displaying results 4471 - 4480 of 10000 in total
  1. Drug

    Edivoxetine

    go.drugbank.com/drugs/DB09184
    Investigational

    Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant … Edivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012.

  2. Drug

    Nerofe

    go.drugbank.com/drugs/DB14786
    Investigational

    Nerofe is under investigation in clinical trial NCT03059615 (A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS).

    Synonyms: TRP-TRP-THR-PHE-PHE-LEU-PRO-SER-THR-LEU-TRP-GLU-ARG-LYS, (ALL D)-
  3. Drug

    Danegaptide

    go.drugbank.com/drugs/DB11821
    Investigational

    Danegaptide has been investigated for the treatment of Focus of Study is STEMI.

  4. Drug

    Acyline

    go.drugbank.com/drugs/DB11906
    Investigational

    Acyline has been investigated for the prevention and treatment of Hypogonadism and Contraception.

  5. Drug

    BMS-777607

    go.drugbank.com/drugs/DB12064
    Investigational

    BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.

  6. Drug

    Tipelukast

    go.drugbank.com/drugs/DB12435
    Investigational

    Tipelukast is under investigation for the treatment of IPF and Idiopathic pulmonary fibrosis.

  7. Drug

    Pf-04531083

    go.drugbank.com/drugs/DB12468
    Investigational

    Pf-04531083 has been investigated for the treatment of Pain and Chronic Pain.

  8. Drug

    Limonene, (+/-)-

    go.drugbank.com/drugs/DB19146
    Investigational

    Limonene, (+/-)- is under investigation in clinical trial NCT05525260 (Limonene for Pulmonary Nodule Chemoprevention).

  9. Drug

    Phenazepam

    go.drugbank.com/drugs/DB19164
    Investigational

    Phenazepam is under investigation in clinical trial NCT03017430 (Pregabalin for Opiate Withdrawal Syndrome).

  10. Drug

    Brentuximab

    go.drugbank.com/drugs/DB05471
    Investigational

    SGN-30 has demonstrated objective antitumor responses as a single agent in phase II clinical trials. … SGN-30 received orphan drug designation from the FDA in July 2003 for Hodgkin lymphoma and in February 2004 for T-cell lymphomas.